GNLX

#3367
Genelux Corporation - Common Stock
3.0 5 USD
-2.24%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
3.05
3.05
Range Annuel
2.29
8.54
Changement quotidien
-2.24%
Changement Mensuel
+21.51%
Evolution sur 6 mois
-44.55%
Changement Annuel
+25.51%
Clôture Précédente
3.1 2
Open
3.0 5
Low
3.0 5
High
3.0 5
Volume
8
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 136.76 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-5.07
ratio cours/chiffre d'affaires
20.26 K

Genelux Corporation - Common Stock

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Nouvelles